Article Versions Notes

Bérard G, Guévremont C, Marcotte N, Schroeder C, Bouchard N, Rajan R on behalf of the Programme de Gestion Thérapeutique des Médicaments (PGTM). Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study). Current Oncology. 2023; 30(3):3251-3262. https://doi.org/10.3390/curroncol30030247

Bérard, Ghislain, Chantal Guévremont, Nathalie Marcotte, Coleen Schroeder, Nicole Bouchard, and Raghu Rajan on behalf of the Programme de Gestion Thérapeutique des Médicaments (PGTM). 2023. "Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)" Current Oncology 30, no. 3: 3251-3262. https://doi.org/10.3390/curroncol30030247

Bérard, G., Guévremont, C., Marcotte, N., Schroeder, C., Bouchard, N., & Rajan, R., on behalf of the Programme de Gestion Thérapeutique des Médicaments (PGTM). (2023). Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study). Current Oncology, 30(3), 3251-3262. https://doi.org/10.3390/curroncol30030247